STADA Pharmaceuticals announces its establishment in the U.S. STADA develops, manufactures and markets generic and branded pharmaceuticals.

STADA Pharmaceuticals, Inc. (STDZF.PK) announces its establishment and operations as the U.S. headquarters of STADA Arzeimittel AG in Bad Vilbel, Germany. STADA is a global pharmaceutical company with 18 subsidiaries in Europe, South America, Asia, and the U.S. With a rigorous focus on growth, STADA develops, manufactures and markets more than 300 prescription and over-the-counter pharmaceutical products worldwide, and ranks among the top ten generics suppliers in the world.

STADA Pharmaceuticals builds its portfolio primarily through acquisitions and in-licensing in three core segments -- generic, branded and specialty pharmaceuticals. This month, the new U.S. Company is relaunching its first branded product for the U.S. market — Rheumatrex® (methotrexate) 2.5 mg tablets for rheumatoid arthritis -- acquired from Wyeth.

“With a century-old history of growth and success in the pharmaceutical industry, and considerable international expansion over the past decade, STADA anticipates achieving the same success in the challenging U.S. market,” said Christian Scheiner, President. “Although our product portfolio concentrates on generics, we are focusing on building a branded portfolio as well, beginning with the relaunch this month of Rheumatrex®, a widely prescribed medication for rheumatoid arthritis.”
STADA Pharmaceuticals established its headquarters in Cranbury, NJ, following the acquisition of products and other assets from a U.S. generics manufacturer in January 2002. The Company also acquired the oral product portfolio of ESI Lederle and additional products from Wyeth.

“STADA is seeking preeminence in the U.S. market through the development of niche products, as well as special services for patients, the medical community and pharmacists," said Luis Vélez, Executive Vice President. “We plan to build our U.S. product portfolio through the introduction of products currently in our European portfolio, and through aggressive in-licensing and acquisition efforts. The dynamic market growth expected in the U.S. for generics, the largest of our core segments, will also support our growth.”

STADA Products:
Through licensing, acquisition and product development, STADA is rapidly expanding its product portfolio of generic, branded and specialty pharmaceuticals. The Company’s generic product line spans a wide range of therapeutic categories, focusing primarily on antibiotics, as well as nonsteroidal anti-inflammatory drugs (NSAIDs), anti-hypertensives and anti-ulcer/ heartburn medications (H2 receptor antagonists). The Company contracts world-class FDA-approved manufacturers in the U.S. and Europe, maintaining flexibility and rapid market responsiveness.
In April 2004, STADA is relaunching Rheumatrex® (methotrexate sodium tablets), a disease modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis, following its acquisition from Wyeth in 2002. Rheumatrex® brand of methotrexate, the most widely prescribed treatment for moderate and severe rheumatoid arthritis, is the only methotrexate available with a comprehensive patient education and compliance program. The once-weekly drug comes in convenient dose packs to encourage safety and compliance.

About STADA Pharmaceuticals, Inc.:
STADA Pharmaceuticals, Inc., headquartered in Cranbury, NJ, is the U.S. subsidiary of STADA Arzeimittel AG in Bad Vilbel, Germany, a global pharmaceutical company with 18 subsidiaries worldwide. STADA Pharmaceuticals develops, manufactures and markets generic, branded and specialty pharmaceuticals throughout the U.S., and ranks among the top ten generics suppliers in the world. For more information, call 1-800-542-6682 or visit www.stadausa.com.

###

CONTACT:    
Marilyn Seiger                       
914-325-5185
mseiger@optonline.net